Thursday - June 5, 2025
ENHERTU (fam-trastuzumab Deruxtecan-nxki) Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% vs. THP as 1st-Line Therapy in Patients
June 03, 2025
WILMINGTON, Delaware, June 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products